Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: Current evidence

Stroke

Volumn 45, Issue 10, 2014, Pages 3032-3039

  Boudreau, Denise M ^a   Guzauskas, Gregory F ^a   Chen, Er ^b   Lalla, Deepa ^c   Tayama, Darren ^b   Fagan, Susan C ^d   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENENTECH INC   (United States)

^c Palo Alto Outcomes Research   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

cerebrovascular disorders; cost effectiveness; quality of life; stroke; thrombolytic drugs

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABLED PERSON; HEALTH CARE COST; HUMAN; LONG TERM CARE; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNCERTAINTY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; STROKE; UNITED STATES;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 84922481886     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005852     Document Type: Article

References (67)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517-584.
3. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125: e2-e220.
4. American Heart Association. Heart disease and stroke. http://www. heart. org/HEARTORG/. Accessed March 4, 2011.
5. Elkins JS, Johnston SC. Thirty-year projections for deaths from ischemic stroke in the United States. Stroke. 2003;34:2109-2112.
6. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123:933-944.
7. The National Institute of Neurological Disorders and Stroke r-tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
9. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
10. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
11. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372.
12. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36:1232-1240.
13. Centers for Disease Control and Prevention (CDC). Use of a registry to improve acute stroke care-seven states, 2005-2009. MMWR Morb Mortal Wkly Rep. 2011;60:206-210.
14. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
15. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-890.
16. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis. 2005;20:193-200.
17. Ehlers L, Andersen G, Clausen LB, Bech M, Kjølby M. Costeffectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007;38:85-89.
18. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4. 5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61:46-55.
19. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al; IST-3 Collaborative Group. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet. 2012;379:2352-2363.
20. Bureau for Labor Statistics. Inflation calculator. http://www. bls. gov/ data/#calculators. Accessed December 20, 2013.
21. Manning WG, Fryback DG, Weinstein M. Reflecting uncertainty in costeffectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein M, eds. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:247-275.
22. Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centers for acute stroke care. Stroke. 2012;43:1617-1623.
23. Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke. 2005;36:777-781.
24. Hong KS, Yegiaian S, Lee M, Lee J, Saver JL. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation. 2011;123:2111-2119.
25. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology. 2003;228:659-668.
26. Eriksson M, Norrving B, Terént A, Stegmayr B. Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis. 2008;25:423-429.
27. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271.
28. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
29. Christensen MC, Mayer S, Ferran JM. Quality of life after intracerebral hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke. 2009;40:1677-1682.
30. Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009;40:1710-1720.
31. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
32. Arias E. United states life tables, 2006. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2010;58:1-40.
33. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P; Oxfordshire Community Stroke Project, the International Stroke Trial (UK); Lothian Stroke Register. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336:376-379.
34. De Wit L, Putman K, Devos H, Brinkmann N, Dejaeger E, De Weerdt W, et al. Five-year mortality and related prognostic factors after inpatient stroke rehabilitation: A European multi-centre study. J Rehabil Med. 2012;44:547-552.
35. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. Costeffectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35:1490-1497.
36. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000;31:2080-2086.
37. Hong KS, Saver JL. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke. 2010;41:471-477.
38. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
39. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4. 5-hour time window for acute ischemic stroke. Stroke. 2011;42:2257-2262.
40. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology. 1994;44:626-634.
41. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke. 1991;22:1236-1241.
42. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
43. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
44. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002;5:82-97.
45. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology. 2001;57:305-314.
46. Analyource Online Web site. The online resource for drug pricing and deal information. https://www. Analysource. com/. Accessed August 26, 2014.
47. Caro JJ, Huybrechts KF. Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke. 1999;30:2574-2579.
48. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
49. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722-732.
50. Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Comput Biomed Res. 1986;19:254-265.
51. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making. 1998;18:S81-S92.
52. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5:157-177.
53. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377-401.
54. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7:723-740.
55. Klok RM, Postma MJ. Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Expert Rev Pharmacoecon Outcomes Res. 2004;4:599-601.
56. Rothwell PM. The high cost of not funding stroke research: A comparison with heart disease and cancer. Lancet. 2001;357:1612-1616.
57. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
58. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: A Canadian healthcare perspective. Pharmacoeconomics. 2001;19:927-936.
59. Moodie ML, Carter R, Mihalopoulos C, Thrift AG, Chambers BR, Donnan GA, et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke. 2004;35:1041-1046.
60. American College of Emergency Physicians; American Academy of Neurology. Clinical policy: use of intravenous t-PA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med. 2013;61:225-243.
61. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480-2488.
62. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol. 2006;63:661-664.
63. Tai YJ, Weir L, Hand P, Davis S, Yan B. Does a 'code stroke' rapid access protocol decrease door-to-needle time for thrombolysis? Intern Med J. 2012;42:1316-1324.
64. Silva GS, Farrell S, Shandra E, Viswanathan A, Schwamm LH. The status of telestroke in the United States: A survey of currently active stroke telemedicine programs. Stroke. 2012;43:2078-2085.
65. Alberts MJ. Stroke centers: proof of concept and the concept of proof. Stroke. 2010;41:1100-1101.
66. Silva GS, Schwamm LH. Review of stroke center effectiveness and other get with the guidelines data. Curr Atheroscler Rep. 2013;15:350.
67. Desai JA, Smith EE. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15:337.